Data gathered: November 27
AI Stock Analysis - Kezar Life Sciences (KZR)
Analysis generated April 11, 2024. Powered by Chat GPT.
Kezar Life Sciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for immune-mediated and oncologic disorders. The company's therapeutic pipeline is geared towards addressing unmet medical needs for patients with autoimmune diseases and cancer. By leveraging its expertise in immunology and cancer biology, Kezar is dedicated to bringing transformative medicines to individuals who require new treatment options.
Stock Alerts - Kezar Life Sciences (KZR)
 |
Kezar Life Sciences | October 31 Price is down by -7.1% in the last 24h. |
|
Kezar Life Sciences | October 30 AI Score is up by 21.4% in the last couple of days. |
|
Kezar Life Sciences | October 30 Price is down by -6.1% in the last 24h. |
|
Kezar Life Sciences | October 21 Price is down by -5% in the last 24h. |
Alternative Data for Kezar Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 17 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 177 | Sign up | Sign up | Sign up |
| Instagram Followers | 199 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,780 | Sign up | Sign up | Sign up |
| Twitter Followers | 522 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 45 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 71 | Sign up | Sign up | Sign up |
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
| Price | $7.40 |
| Target Price | Sign up |
| Volume | 6,440 |
| Market Cap | $55M |
| Year Range | $5.29 - $9.75 |
| Dividend Yield | 0% |
| Analyst Rating | 25% buy |
| Industry | Biotechnology |
In the news
 |
Head to Head Analysis: Summit Therapeutics (NASDAQ:SMMT) vs. Kezar Life Sciences (NASDAQ:KZR)November 22 - ETF Daily News |
|
William Blair Has Optimistic Outlook of KZR FY2024 EarningsNovember 18 - ETF Daily News |
 |
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12 - Yahoo |
 |
Kezar Life Sciences (NASDAQ:KZR) Shares Gap Down - Here's What HappenedOctober 30 - Biztoc.com |
Kezar Life Sciences trading halted, news pendingOctober 28 - Thefly.com |
|
 |
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR)October 28 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 5.7M | -5.7M | -20M | 0 | 0.000 |
| Q2 '24 | 0 | 7.1M | -7.1M | -22M | -22M | -0.270 |
| Q1 '24 | 0 | 6.5M | -6.9M | -22M | -23M | -0.300 |
| Q4 '23 | -5.4M | 14M | -14M | -32M | -28M | -0.440 |
| Q3 '23 | 6.6M | 8.8M | -2.2M | -23M | -26M | -0.320 |
Insider Transactions View All
| Schiller Mark C. filed to sell 33,007 shares at $0.6. July 26 '24 |
| Morningside Venture Investments Ltd filed to sell 5,447,993 shares at $6.9. February 7 '23 |
| Morningside Venture Investments Ltd filed to sell 5,487,993 shares at $7.1. February 7 '23 |
| Morningside Venture Investments Ltd filed to sell 5,512,993 shares at $7.2. February 3 '23 |
| Morningside Venture Investments Ltd filed to sell 5,562,993 shares at $7. February 3 '23 |
Similar companies
Read more about Kezar Life Sciences (KZR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Kezar Life Sciences?
The Market Cap of Kezar Life Sciences is $55M.
What is the current stock price of Kezar Life Sciences?
Currently, the price of one share of Kezar Life Sciences stock is $7.40.
How can I analyze the KZR stock price chart for investment decisions?
The KZR stock price chart above provides a comprehensive visual representation of Kezar Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kezar Life Sciences shares. Our platform offers an up-to-date KZR stock price chart, along with technical data analysis and alternative data insights.
Does KZR offer dividends to its shareholders?
As of our latest update, Kezar Life Sciences (KZR) does not offer dividends to its shareholders. Investors interested in Kezar Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kezar Life Sciences?
Some of the similar stocks of Kezar Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.